Nobuhide Kobayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nobuhide Kobayashi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Takuhiro Matsumura
Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University
5 shared publications - Yukako Fujinaga
Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University
5 shared publications Aki Yamaguchi
Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University
4 shared publications- Sho Amatsu
Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University
4 shared publications Kanon Iwata
Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University
3 shared publications- Kazuki Saito
Department of Bacteriology, Graduate School of Medical Sciences, Kanazawa University
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by American Society for Microbiology in mSphere
An antibiotic-treated mouse model reveals the progression of intestinal botulism
Intestinal botulism, including infant botulism and adult intestinal toxemia botulism, is a life-threatening disease caused by intestinal infection with Clostridium botulinum ( Cb ) spores. Infants are particularly susceptible to Cb infection because of their immature gut microbiota, whereas healthy adults are generally protected by gut microbiota-mediated colonization resistance. Thus, immature gut microbiota or gut dysbiosis is thought to permit Cb colonization. However, the mechanisms underlying colonization resistance and disease progression remain poorly characterized. Here, using adult mice with antibiotic-induced dysbiosis, we established a model for studying Cb infection and characterized intestinal colonization, bacterial expansion, botulinum neurotoxin (BoNT) accumulation, and disease progression during intestinal botulism. Intestinal botulism developed in antibiotic-treated mice after intragastric administration of strain 62A spores, whereas untreated adult mice showed no symptoms. In antibiotic-treated mice, Cb expanded over time in fecal samples, followed by accumulation of serotype A BoNT (BoNT/A), which correlated with the progression of botulism symptoms. Cb growth and BoNT/A accumulation occurred mainly in the cecum and colon, but not in the small intestine. Furthermore, this mouse model was applicable to the analysis of intestinal botulism caused by other Cb strains, including 7I03-H, Okra, and Osaka05. Taken together, our findings clarify key aspects of intestinal botulism pathogenesis. This mouse model may provide a useful platform for elucidating the mechanisms underlying intestinal botulism, including infant botulism, and for developing novel therapeutic strategies. IMPORTANCE: Botulism is a life-threatening disease caused by botulinum neurotoxin, one of the most powerful toxins known. In intestinal botulism, Clostridium botulinum spores enter the intestine, grow there, and release toxin inside the body. However, the detailed process by which intestinal botulism develops remains poorly understood. In this study, we established a mouse model that allows the progression of intestinal botulism to be examined over time. Using this model, we showed that bacterial growth in the intestine, accumulation of biologically active toxins, and worsening of symptoms are closely linked. We also identified the cecum and colon as the main sites of bacterial colonization and toxin accumulation. This model can be used to analyze multiple C. botulinum strains with different characteristics and provides a useful tool for understanding how intestinal botulism develops and for guiding future preventive and therapeutic strategies.
- 10 November 2026
- Published by American Society for Microbiology in mSphere
Open AccessAn antibiotic-treated mouse model reveals the progression of intestinal botulism
Intestinal botulism, including infant botulism and adult intestinal toxemia botulism, is a life-threatening disease caused by intestinal infection with Clostridium botulinum ( Cb ) spores. Infants are particularly susceptible to Cb infection because of their immature gut microbiota, whereas healthy adults are generally protected by gut microbiota-mediated colonization resistance. Thus, immature gut microbiota or gut dysbiosis is thought to permit Cb colonization. However, the mechanisms underlying colonization resistance and disease progression remain poorly characterized. Here, using adult mice with antibiotic-induced dysbiosis, we established a model for studying Cb infection and characterized intestinal colonization, bacterial expansion, botulinum neurotoxin (BoNT) accumulation, and disease progression during intestinal botulism. Intestinal botulism developed in antibiotic-treated mice after intragastric administration of strain 62A spores, whereas untreated adult mice showed no symptoms. In antibiotic-treated mice, Cb expanded over time in fecal samples, followed by accumulation of serotype A BoNT (BoNT/A), which correlated with the progression of botulism symptoms. Cb growth and BoNT/A accumulation occurred mainly in the cecum and colon, but not in the small intestine. Furthermore, this mouse model was applicable to the analysis of intestinal botulism caused by other Cb strains, including 7I03-H, Okra, and Osaka05. Taken together, our findings clarify key aspects of intestinal botulism pathogenesis. This mouse model may provide a useful platform for elucidating the mechanisms underlying intestinal botulism, including infant botulism, and for developing novel therapeutic strategies. IMPORTANCE: Botulism is a life-threatening disease caused by botulinum neurotoxin, one of the most powerful toxins known. In intestinal botulism, Clostridium botulinum spores enter the intestine, grow there, and release toxin inside the body. However, the detailed process by which intestinal botulism develops remains poorly understood. In this study, we established a mouse model that allows the progression of intestinal botulism to be examined over time. Using this model, we showed that bacterial growth in the intestine, accumulation of biologically active toxins, and worsening of symptoms are closely linked. We also identified the cecum and colon as the main sites of bacterial colonization and toxin accumulation. This model can be used to analyze multiple C. botulinum strains with different characteristics and provides a useful tool for understanding how intestinal botulism develops and for guiding future preventive and therapeutic strategies.
- Open Access
LRP1 is an entry receptor for the botulinum toxin complex in the gut
Botulinum neurotoxin (BoNT) is an etiologic agent of food poisoning caused by Clostridium botulinum . The large progenitor toxin complex (L-PTC) crosses the intestinal epithelial barrier to deliver BoNT to target neurons; however, it is not clearly understood how BoNT enters the host. Here, we identified low-density lipoprotein receptor−related protein 1 (LRP1) as a major enterocyte transcytosis receptor for the hyper-oral-toxic L-PTC serotype B-Okra (L-PTC/B Okra ). We found that hemagglutinin (HA), a neurotoxin-associated protein within the L-PTC/B Okra complex, binds to LRP1 via N -glycans. HA/B Okra co-localized with LRP1 within the internalized vesicles in cultured cells and enterocytes. LRP1 deletion inhibited the apical-to-basal transcytosis of L-PTC/B Okra in an intestinal epithelial cell line, and this effect was rescued by LRP1 re-expression. Finally, intestinal epithelial cell−specific LRP1-deficient mice displayed reduced susceptibility to toxicity caused by oral administration of L-PTC/B Okra . Taken together, these results indicate that N -glycosylated LRP1 mediates L-PTC/B Okra transcytosis via enterocytes, enabling BoNT to traverse the intestinal epithelial barrier.
Open AccessLRP1 is an entry receptor for the botulinum toxin complex in the gut
Botulinum neurotoxin (BoNT) is an etiologic agent of food poisoning caused by Clostridium botulinum . The large progenitor toxin complex (L-PTC) crosses the intestinal epithelial barrier to deliver BoNT to target neurons; however, it is not clearly understood how BoNT enters the host. Here, we identified low-density lipoprotein receptor−related protein 1 (LRP1) as a major enterocyte transcytosis receptor for the hyper-oral-toxic L-PTC serotype B-Okra (L-PTC/B Okra ). We found that hemagglutinin (HA), a neurotoxin-associated protein within the L-PTC/B Okra complex, binds to LRP1 via N -glycans. HA/B Okra co-localized with LRP1 within the internalized vesicles in cultured cells and enterocytes. LRP1 deletion inhibited the apical-to-basal transcytosis of L-PTC/B Okra in an intestinal epithelial cell line, and this effect was rescued by LRP1 re-expression. Finally, intestinal epithelial cell−specific LRP1-deficient mice displayed reduced susceptibility to toxicity caused by oral administration of L-PTC/B Okra . Taken together, these results indicate that N -glycosylated LRP1 mediates L-PTC/B Okra transcytosis via enterocytes, enabling BoNT to traverse the intestinal epithelial barrier.
- Open Access
Acquisition of Stickland-metabolizing bacteria during infancy prevents Clostridium botulinum infection
The mechanisms by which maturation of the infant gut microbiota promotes resistance to pathogen colonization remain poorly understood. Infant botulism, a potentially fatal disease caused by intestinal colonization by Clostridium botulinum, provides a striking example of age-dependent susceptibility to infection. Although the gut microbiota has long been implicated in protection against C. botulinum, the responsible bacterial species and underlying mechanisms have yet to be elucidated. Here, we show that acquisition of Stickland-metabolizing Clostridia during infant gut microbiota maturation confers resistance to C. botulinum colonization through competition for shared amino-acid-dependent nutritional niches. In human fecal microbiota-transplanted mice, longitudinally collected infant microbiotas exhibited a clear transition from susceptibility to resistance. Intestinal metabolomic analysis identified 5-aminovalerate as a hallmark metabolite of the resistant microbiota, implicating Stickland metabolism, an amino acid metabolic pathway also utilized by C. botulinum. Guided by this finding, metagenomic analysis revealed enrichment of Stickland-metabolizing Clostridia in resistant microbiotas, including Clostridioides difficile, a bacterium frequently carried by healthy infants. Intestinal metabolic signatures of C. botulinum and infant-derived Stickland-metabolizing Clostridia suggested competition for shared amino-acid-dependent nutritional niches. Consistent with this model, C. difficile suppressed C. botulinum expansion through nutrient competition. Together, these findings identify nutritional niche competition as a mechanism by which microbiota maturation promotes resistance to C. botulinum colonization. This work demonstrates how acquisition of specific microbial metabolic functions during early life can shift the gut microbiota from a susceptible to a resistant state.
Open AccessAcquisition of Stickland-metabolizing bacteria during infancy prevents Clostridium botulinum infection
The mechanisms by which maturation of the infant gut microbiota promotes resistance to pathogen colonization remain poorly understood. Infant botulism, a potentially fatal disease caused by intestinal colonization by Clostridium botulinum, provides a striking example of age-dependent susceptibility to infection. Although the gut microbiota has long been implicated in protection against C. botulinum, the responsible bacterial species and underlying mechanisms have yet to be elucidated. Here, we show that acquisition of Stickland-metabolizing Clostridia during infant gut microbiota maturation confers resistance to C. botulinum colonization through competition for shared amino-acid-dependent nutritional niches. In human fecal microbiota-transplanted mice, longitudinally collected infant microbiotas exhibited a clear transition from susceptibility to resistance. Intestinal metabolomic analysis identified 5-aminovalerate as a hallmark metabolite of the resistant microbiota, implicating Stickland metabolism, an amino acid metabolic pathway also utilized by C. botulinum. Guided by this finding, metagenomic analysis revealed enrichment of Stickland-metabolizing Clostridia in resistant microbiotas, including Clostridioides difficile, a bacterium frequently carried by healthy infants. Intestinal metabolic signatures of C. botulinum and infant-derived Stickland-metabolizing Clostridia suggested competition for shared amino-acid-dependent nutritional niches. Consistent with this model, C. difficile suppressed C. botulinum expansion through nutrient competition. Together, these findings identify nutritional niche competition as a mechanism by which microbiota maturation promotes resistance to C. botulinum colonization. This work demonstrates how acquisition of specific microbial metabolic functions during early life can shift the gut microbiota from a susceptible to a resistant state.
- Open Access
An Antibiotic-Treated Mouse Model Reveals the Progression of Intestinal Botulism
Intestinal botulism, including infant botulism and adult intestinal toxemia botulism, is a life-threatening disease caused by intestinal infection with Clostridium botulinum ( Cb ) spores. Infants are particularly susceptible to Cb infection because of their immature gut microbiota, whereas healthy adults are generally protected by gut microbiota-mediated colonization resistance. Thus, immature gut microbiota or gut dysbiosis is thought to permit Cb colonization. However, the mechanisms underlying colonization resistance and disease progression remain poorly characterized. Here, using adult mice with antibiotic-induced dysbiosis, we established a model for studying Cb infection and characterized intestinal colonization, bacterial expansion, botulinum neurotoxin (BoNT) accumulation, and disease progression during intestinal botulism. Intestinal botulism developed in antibiotic-treated mice after intragastric administration of strain 62A spores, whereas untreated adult mice showed no symptoms. In antibiotic-treated mice, Cb expanded over time in fecal samples, followed by accumulation of serotype A BoNT (BoNT/A), which correlated with the progression of botulism symptoms. Cb growth and BoNT/A accumulation occurred mainly in the cecum and colon, but not in the small intestine. Furthermore, this mouse model waapplicable to the analysis of intestinal botulism caused by other Cb strains, including 7I03-H, Okra, and Osaka05. Taken together, our findings clarify key aspects of intestinal botulism pathogenesis. This mouse model may provide a useful platform for elucidating the mechanisms underlying intestinal botulism, including infant botulism, and for developing novel therapeutic strategies. Importance: Botulism is a life-threatening disease caused by botulinum neurotoxin, one of the most powerful toxins known. In intestinal botulism, Clostridium botulinum spores enter the intestine, grow there, and release toxin inside the body. However, the detailed process by which intestinal botulism develops remains poorly understood. In this study, we established a mouse model that allows the progression of intestinal botulism to be examined over time. Using this model, we showed that bacterial growth in the intestine, accumulation of biologically active toxin, and worsening of symptoms are closely linked. We also identified the cecum and colon as the main sites of bacterial colonization and toxin accumulation. This model can be used to analyze multiple C. botulinum strains with different characteristics and provides a useful tool for understanding how intestinal botulism develops and for guiding future preventive and therapeutic strategies.
Open AccessAn Antibiotic-Treated Mouse Model Reveals the Progression of Intestinal Botulism
Intestinal botulism, including infant botulism and adult intestinal toxemia botulism, is a life-threatening disease caused by intestinal infection with Clostridium botulinum ( Cb ) spores. Infants are particularly susceptible to Cb infection because of their immature gut microbiota, whereas healthy adults are generally protected by gut microbiota-mediated colonization resistance. Thus, immature gut microbiota or gut dysbiosis is thought to permit Cb colonization. However, the mechanisms underlying colonization resistance and disease progression remain poorly characterized. Here, using adult mice with antibiotic-induced dysbiosis, we established a model for studying Cb infection and characterized intestinal colonization, bacterial expansion, botulinum neurotoxin (BoNT) accumulation, and disease progression during intestinal botulism. Intestinal botulism developed in antibiotic-treated mice after intragastric administration of strain 62A spores, whereas untreated adult mice showed no symptoms. In antibiotic-treated mice, Cb expanded over time in fecal samples, followed by accumulation of serotype A BoNT (BoNT/A), which correlated with the progression of botulism symptoms. Cb growth and BoNT/A accumulation occurred mainly in the cecum and colon, but not in the small intestine. Furthermore, this mouse model waapplicable to the analysis of intestinal botulism caused by other Cb strains, including 7I03-H, Okra, and Osaka05. Taken together, our findings clarify key aspects of intestinal botulism pathogenesis. This mouse model may provide a useful platform for elucidating the mechanisms underlying intestinal botulism, including infant botulism, and for developing novel therapeutic strategies. Importance: Botulism is a life-threatening disease caused by botulinum neurotoxin, one of the most powerful toxins known. In intestinal botulism, Clostridium botulinum spores enter the intestine, grow there, and release toxin inside the body. However, the detailed process by which intestinal botulism develops remains poorly understood. In this study, we established a mouse model that allows the progression of intestinal botulism to be examined over time. Using this model, we showed that bacterial growth in the intestine, accumulation of biologically active toxin, and worsening of symptoms are closely linked. We also identified the cecum and colon as the main sites of bacterial colonization and toxin accumulation. This model can be used to analyze multiple C. botulinum strains with different characteristics and provides a useful tool for understanding how intestinal botulism develops and for guiding future preventive and therapeutic strategies.
- 6 September 2024
- Published by Wiley in Microbiology and Immunology
- Vol. 68 (10) , 348-358
Neutralization mechanism of human monoclonal antibodies against type B botulinum neurotoxin
Botulism is a deadly neuroparalytic condition caused by the botulinum neurotoxin (BoNT) produced by Clostridium botulinum and related species. Toxin‐neutralizing antibodies are the most effective treatments for BoNT intoxication. We generated human monoclonal antibodies neutralizing type B botulinum neurotoxin (BoNT/B), designated M2 and M4. The combination of these antibodies exhibited a strong neutralizing effect against BoNT/B toxicity. In this study, we analyzed the mechanisms of action of these antibodies in vitro. M4 binds to the C‐terminus of the heavy chain (the receptor‐binding domain) and inhibits BoNT/B binding to neuronal PC12 cells. Although M2 recognized the light (L) chain (the metalloprotease domain), it did not inhibit substrate (VAMP2) cleavage in the cleavage assay. M2 increased the surface localization of BoNT/B in PC12 cells at a later time point, suggesting that M2 inhibits the translocation of the L chain from synaptic vesicles to the cytosol. These results indicate that M2 and M4 inhibit the different processes of BoNT/B individually and that multistep inhibition is important for the synergistic effect of the combination of monoclonal antibodies. Our findings may facilitate the development of effective therapeutic antibodies against BoNTs.
- 6 September 2024
- Published by Wiley in Microbiology and Immunology
- Vol. 68 (10) , 348-358
Neutralization mechanism of human monoclonal antibodies against type B botulinum neurotoxin
Botulism is a deadly neuroparalytic condition caused by the botulinum neurotoxin (BoNT) produced by Clostridium botulinum and related species. Toxin‐neutralizing antibodies are the most effective treatments for BoNT intoxication. We generated human monoclonal antibodies neutralizing type B botulinum neurotoxin (BoNT/B), designated M2 and M4. The combination of these antibodies exhibited a strong neutralizing effect against BoNT/B toxicity. In this study, we analyzed the mechanisms of action of these antibodies in vitro. M4 binds to the C‐terminus of the heavy chain (the receptor‐binding domain) and inhibits BoNT/B binding to neuronal PC12 cells. Although M2 recognized the light (L) chain (the metalloprotease domain), it did not inhibit substrate (VAMP2) cleavage in the cleavage assay. M2 increased the surface localization of BoNT/B in PC12 cells at a later time point, suggesting that M2 inhibits the translocation of the L chain from synaptic vesicles to the cytosol. These results indicate that M2 and M4 inhibit the different processes of BoNT/B individually and that multistep inhibition is important for the synergistic effect of the combination of monoclonal antibodies. Our findings may facilitate the development of effective therapeutic antibodies against BoNTs.